Previous 10 | Next 10 |
Exagen (XGN): Q1 GAAP EPS of -$0.48 misses by $0.03.Revenue of $10.6M (+10.6% Y/Y) beats by $0.15M.Press Release For further details see: Exagen EPS misses by $0.03, beats on revenue
Quarterly Records: AVISE ® CTD Volumes, Ordering Healthcare Providers and Adopters SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended Marc...
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, Allegheny Health Network (AHN) Research Institute and the AHN Autoimmunity Institute jointly announced today the execution of a research colla...
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awareness initiatives and educational tools highlighting the importance of an accurate...
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after the market close on Tuesday, May 11, 2021. Ron Rocca, Exagen’s President an...
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term ...
Gainers: [[UEPS]] +4.61%. [[XGN]] +4.5%. [[DISCA]] +4.1%. [[CARG]] +3.3%. [[APTX]] +3.0%.Losers: [[EWTX]] -6.7%. [[NVAX]] -6.6%. [[AACG]] -6.5%. [[IKNA]] -5.9%. [[LSXMK]] -4.5%. For further details see: UEPS, XGN, IKNA and NVAX among after-hours movers
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold p...
Exagen (XGN) has priced its public offering of 3.7M common shares at $16.25/share, for expected gross proceeds of $60.1M.Underwriters' over-allotment is an additional 555K shares. Net proceeds will be used for build out of clinical laboratory, advancement of its product pipeline, for working ...
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,000 shares of its common stock at a price to the public of $16.25 per share. All of the s...
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...